You have access
Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
SHAWN L. PETERSON, MUHAMMAD HUSNAIN, TERRI POLLACK, AGUSTIN PIMENTEL, ARTURO LOAIZA-BONILLA, COLLEEN WESTENDORF-OVERLEY, KELLEY RATERMANN, LOWELL ANTHONY, PHILIP DESIMONE, GAURAV GOEL, MAHESH KUDRIMOTI, SEAN DINEEN, CHING-WEI D. TZENG and PETER J. HOSEIN
Anticancer Research July 2018, 38 (7) 4035-4039; DOI: https://doi.org/10.21873/anticanres.12692